Free Trial
→ Many investors are about to lose everything (From Porter & Company) (Ad)tc pixel
NASDAQ:SBFM

Sunshine Biopharma Earnings Date & Estimates

Sunshine Biopharma logo
$2.83 +0.08 (+2.91%)
As of 02:15 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sunshine Biopharma is estimated to report earnings on Thursday, November 12, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Sunshine Biopharma

Sunshine Biopharma is expected to post earnings of -$3.40 per share on revenue of $9.60 million. In the same quarter a year earlier Sunshine Biopharma reported -$38.00 per share on revenue of $9.42 million. Sunshine Biopharma last reported on August 13, 2026, posting -$23.00 per share and beating the -$24.00 consensus estimate. Sunshine Biopharma has beaten the consensus EPS estimate in 2 of its last 5 quarters.

Consensus Estimates

Consensus EPS
-$3.40
Expected Revenue
$9.60 million
Prior-Year EPS
-$38.00
Prior-Year Revenue
$9.42 million
Expected Revenue Growth
+1.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$23.00 (Beat by +$1.00)
Last Quarter Revenue
$9.26 million
EPS Beat Rate
2 of last 5 quarters

Prepare for the Earnings Call

Sunshine Biopharma Earnings FAQ

Sunshine Biopharma (NASDAQ:SBFM) is estimated to report earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Sunshine Biopharma to post earnings of -$3.40 per share for the quarter.

The consensus revenue estimate for Sunshine Biopharma is $9.60 million for the quarter.

Sunshine Biopharma Earnings Headlines

Sunshine Biopharma (SBFM) Set to Post Quarterly Earnings on Thursday
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31179294
Sunshine Biopharma (SBFM) AI Stock Analysis
November 3, 2026  |  tipranks.comhttps://www.tipranks.com/stocks/sbfm/stock-analysis
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
November 10 at 1:00 AM  |  Behind the Markets (Ad)
Sunshine Biopharma consensus price target raised 1,900% to $1,142.40
November 1, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/sunshine-biopharma-consensus-price-target-raised-1-900-to-1-142-40/ar-AA2gy72S
Sunshine Biopharma (NASDAQ:SBFM) Stock Rating Upgraded by Wall Street Zen
October 31, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31168682
Sunshine Biopharma Prices $6 Million Public Offering; Stock Down
October 8, 2026  |  rttnews.comhttps://www.rttnews.com/3697567/sunshine-biopharma-prices-6-million-public-offering-stock-down.aspx
See More Sunshine Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sunshine Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sunshine Biopharma and other key companies, straight to your email.

About Sunshine Biopharma

Sunshine Biopharma (NASDAQ:SBFM) is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors.

In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations. The company has been associated with the distribution and commercialization of prescription and over-the-counter products in Canada, including generic medicines and other healthcare products.

Sunshine Biopharma is headquartered in Canada and has conducted its pharmaceutical and biotechnology activities primarily through its Canadian operations. The company has identified Steve Slilaty as its chief executive officer and has traded on the Nasdaq Capital Market under the symbol SBFM. Its business combines the development of proprietary oncology candidates with pharmaceutical product commercialization.

View Sunshine Biopharma Profile
Earnings Tools